Clinical Trial List
The Angeles Clinic & Research Institute is currently enrolling participants in clinical trials for:
Basal Cell Carcinoma
A Pivotal Phase II, Multicenter, Single Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients with Advanced Basel Cell Carcinoma
Go back to the top
Brain Tumors
The Temodar Combination Study
Go back to the top
Breast Cancer
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
An Open-Label, Randomized, Adaptive Design, Two-Period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anti-Cancer Treatment in Patients with Solid Tumors.
Go back to the top
Lung Cancer
APRICOT-L : A Randomized, Double Blind, Placebo Controlled Multicenter
Phase 2Study of the Efficay and Safety of Apricoxib in Combination with Erlotinib in Non-Small Lung Cancer Patients
Go back to the top
Melanoma
Adjuvant Therapy
A Randomized, Double-Blind Phase III Trial of Adjuvant Immunotherapy with Ipilimumab vs. Placebo After Complete Resection of High-Risk Stage III Melanoma
A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 ASCI as Adjuvant Therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma
Melanoma - First Line Therapy
An Open, Single-Arm Trial to Assess the Clinical Activity of recMAGE-A3 + AS15 in Patients with Unresectable MAGE-A3-Positive Stage III or Stage IVA Metastatic Cutaneous Melanoma
A Study of RO5185426 (BRAF therapy) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma
A Phase Ib/II Study of ALT-801 with Cisplatin in Patients with Metastatic Melanoma
Melanoma – Second Line Therapy
A Randomized, Phase III Study of LY573636 (Tasisulam) Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
Melanoma – Pretreated/Any Line
A Phase I, Open-Label, Dose-Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Melanoma
A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
A Phase II, Open Label, NonRandomized Study to Evaluate the Safety, Tolerability, Immune Response, and Clinical Response of Multiple Doses of MKC1106-MT in Subjects with Advanced Melanoma
A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
A Phase I, Multicenter, Open Label, Dose Escalation, Safety Study of E6201 in subjects with Advanced Solid Tumors
Melanoma - Brain Metastasis
A Phase II Trial of Temozolomide plus Bevacizumab in Patients with Metastatic Melanoma Involving the Central Nervous System
Melanoma – Acral and Mucosal
A Phase II study of Imatinib (Gleevec) in Patients with Mucosal or Acral/Lentiginous Melanoma or Melanomas that arise on Chronically Sun Damaged Skin
A Phase II Study of Sentinel Therapy for Patients with Metastatic Melanoma and KIT Gene Aberrations
A Phase II Study of Nilotinib in TKI Resistant or Intolerant Patients with Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Go back to the top
Prostate Cancer
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
A Randomized, Double-Blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
Go back to the top
Phase I / Any Tumor
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination with Either Gemcitabine, Cisplatin, or Carboplatin in Adult Patients With Advanced Solid Tumors
An Open-Label, Randomized, Adaptive Design, Two-Period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anti-Cancer Treatment in Patients with Solid Tumors
A Phase I, Multicenter, Open Label, Dose Escalation, Safety Study of E6201 in subjects with Advanced Solid Tumors
Ovarian cancer
Colorectal Cancer
Pancreatic Cancer
Gastointestinal Cancer
Go back to the top